# TAU R406W Research Report **Protein:** TAU R406W **Variant:** R406W **UniProt ID:** P10636 **Disease Association:** Alzheimer's disease **Report Generated:** 2026-07-28 20:21 UTC **AlphaFold Confidence (pLDDT):** 55.0% **Structure Folded:** 2026-07-14 --- ## Structure Summary The R406W mutation in tau protein replaces a positively charged arginine with a bulky tryptophan near tau's C-terminal end, a region critical for regulating tau's interactions with other proteins and its cellular localization in Alzheimer's disease. The AlphaFold2 structure prediction shows very low confidence (pLDDT 55.0) across the protein, indicating this region is likely disordered and highly flexible in solution. This intrinsic disorder may facilitate abnormal protein interactions that promote tau aggregation and spreading between neurons, as recent research shows R406W tau causes neurodegeneration in fruit fly models of tauopathy. --- The R406W mutation in the tau protein (encoded by the MAPT gene) occurs in the C-terminal region at position 406, where it substitutes a positively charged arginine with a large, hydrophobic tryptophan residue. This region lies beyond tau's microtubule-binding repeats and is involved in regulating tau's interactions with cellular membranes, other proteins, and its own aggregation propensity. Recent experimental work demonstrates that tauR406W causes significant neurodegeneration in Drosophila melanogaster models, producing tau-induced deficits that can be ameliorated under simulated microgravity conditions [2]. The mutation has been studied in the context of tauopathies, the class of neurodegenerative diseases characterized by abnormal tau protein accumulation that includes Alzheimer's disease and frontotemporal dementia. The AlphaFold2 structure prediction for tau R406W exhibits an average confidence score (pLDDT) of 55.0, which falls well below the threshold of 70 typically required for reliable structural interpretation. This very low confidence indicates that the protein, particularly in its C-terminal region where R406W resides, is intrinsically disordered rather than adopting a stable three-dimensional structure. Intrinsically disordered regions in tau are functionally important: they remain flexible in solution and can adopt multiple conformations, allowing tau to interact with diverse binding partners. However, this structural flexibility also makes these regions vulnerable to pathological changes, as they can more easily misfold and aggregate into the neurofibrillary tangles characteristic of Alzheimer's disease. The R406W substitution likely disrupts normal electrostatic interactions in tau's C-terminal region, potentially affecting how tau interacts with negatively charged cellular components like membranes and nucleic acids. The replacement of arginine's positive charge with tryptophan's aromatic ring may also promote abnormal hydrophobic interactions that facilitate tau aggregation. Recent genomic studies have identified that neurons in Alzheimer's disease, frontotemporal dementia, and ALS accumulate DNA damage and somatic mutations, with tau proteinopathies sharing common patterns of genomic instability [3]. Additionally, post-translational modifications throughout the tau protein are increasingly recognized as critical contributors to Alzheimer's disease pathology and cognitive decline [4], suggesting that the R406W mutation may alter the protein's susceptibility to phosphorylation and other modifications that regulate its function. The low structural confidence for this tau variant reflects an inherent challenge in modeling intrinsically disordered proteins, but also provides important biological insight: the C-terminal region's flexibility may be essential for tau's normal function in stabilizing microtubules and regulating axonal transport. The clinical relevance of understanding C-terminal tau mutations is underscored by ongoing research into therapeutic strategies targeting tau pathology, including gamma-secretase modulators for amyloid processing [5] and investigations into genetic factors like JARID2 that influence cerebral tau deposition [1]. While the R406W mutation itself is studied primarily in experimental models, characterizing how specific amino acid changes affect tau's disordered regions contributes to understanding the molecular mechanisms by which tau dysfunction drives neurodegeneration across multiple disease contexts. ## Works Cited [1] Gunasekaran et al. (2026). Common and rare variant analyses implicate JARID2 in cerebral tau deposition. NPJ dementia. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42404994/) [2] Park et al. (2026). Time-averaged simulated microgravity ameliorates tau-induced deficit in Drosophila melanogaster. NPJ microgravity. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42386756/) [3] Zhou et al. (2026). Recurrent patterns of TOP1-mediated neuronal genomic damage shared by major neurodegenerative disorders. Cell. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42385702/) [4] Libby et al. (2026). Post-translational modifications in the brain are critical contributors to Alzheimer's disease neuropathology and cognitive decline. bioRxiv : the preprint server for biology. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42327232/) [5] Lindemann et al. (2026). Pharmacology of nivegacetor (RG6289), a potent and selective gamma secretase modulator in clinical development for the treatment of Alzheimer's disease. Frontiers in pharmacology. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42292846/) ## Similar Research **Biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno-Sandwich Assay.** Ashton et al. (2025) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40401628/) **Proteomic analysis reveals distinct cerebrospinal fluid signatures across genetic frontotemporal dementia subtypes.** Sogorb-Esteve et al. (2025) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/39908349/) **Protein quality control systems in neurodegeneration - culprits, mitigators, and solutions?** Ciechanover et al. (2025) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40969213/) **Melatonin-Mediated Nrf2 Activation as a Potential Therapeutic Strategy in Mutation-Driven Neurodegenerative Diseases.** Inigo-Catalina et al. (2025) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41154499/) **Alzheimer's Disease Continuum: Evaluating the Relationship between Fluid Biomarkers and Patients' Phenotype and Profile.** Gerlando et al. (2026) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41619269/) --- ## Open Targets Disease Associations | Disease | Score | Data Sources | |---------|-------|--------------| | frontotemporal dementia | 0.789 | genetic_literature, clinical, literature, genetic_association, animal_model | | Pick disease | 0.757 | literature, animal_model, genetic_association, genetic_literature | | supranuclear palsy, progressive, 1 | 0.725 | literature, animal_model, genetic_association, genetic_literature | | Progressive supranuclear palsy - parkinsonism | 0.715 | literature, animal_model, genetic_association, genetic_literature | | Atypical progressive supranuclear palsy | 0.715 | literature, animal_model, genetic_association, genetic_literature | | Classical progressive supranuclear palsy | 0.696 | literature, animal_model, genetic_association, genetic_literature | | progressive supranuclear palsy-parkinsonism syndrome | 0.647 | animal_model, genetic_association, genetic_literature | | late-onset Parkinson disease | 0.639 | literature, animal_model, genetic_association, genetic_literature | | semantic dementia | 0.639 | literature, animal_model, genetic_association, genetic_literature | | progressive supranuclear palsy | 0.614 | genetic_literature, clinical, literature, genetic_association, animal_model | *...and 3339 more associations* --- ## AI Research Brief # Research Brief: TAU R406W Variant ## Pathogenic Mechanisms The TAU R406W variant represents a point mutation in the microtubule-associated protein tau (MAPT), substituting arginine with tryptophan at position 406. This mutation occurs within a functionally critical region of the tau protein, which normally participates in actin binding, apolipoprotein binding, and DNA binding activities. The R406W substitution likely disrupts normal tau-cytoskeletal interactions and cellular homeostasis through multiple mechanisms. Given tau's established role in amyloid fibril formation and its interactions with key pathology-associated proteins including HSP90AB1, GSK3B, and SNCA, this variant may enhance pathogenic aggregation propensity or alter normal proteostatic regulation. The mutation's position suggests potential interference with tau's biological processes including axon development and astrocyte activation, which are critical for neuronal health and synaptic function. The charge-altering nature of the arginine-to-tryptophan substitution (positive to hydrophobic) may destabilize protein conformation and promote aberrant protein-protein interactions. ## Clinical Significance The R406W variant is associated with Alzheimer's disease pathology, though specific clinical data regarding pathogenicity classification and population frequency remain limited in current databases. The mutation's location within functionally important domains and its impact on conserved residues suggest likely pathogenic consequences. Functional impacts are expected to include disrupted microtubule binding, altered phosphorylation patterns, and potentially enhanced aggregation. The variant may contribute to autosomal dominant inheritance patterns observed in familial Alzheimer's disease cases, though additional clinical characterization is needed to establish definitive genotype-phenotype correlations. ## Therapeutic Landscape Structural analysis has identified aggregation hotspots in tau, particularly at residues 542-546 (aggregation score: 0.60), representing a promising therapeutic target. The computationally-generated candidate peptide CP-TAU-001 specifically targets this 542-546 region, offering a rational approach to inhibit pathogenic tau aggregation. This peptide-based strategy aims to interfere with the nucleation and propagation of tau fibrils, a hallmark of tauopathies. The identification of specific aggregation-prone sequences provides mechanistic insight for developing both peptide inhibitors and small molecule therapeutics that could prevent or reverse tau pathological assembly. ## Research Directions Critical knowledge gaps include: (1) comprehensive structural characterization of the R406W variant's impact on tau folding and aggregation kinetics, (2) clinical penetrance and phenotypic variability studies in affected families, (3) experimental validation of CP-TAU-001 efficacy in cellular and animal models, and (4) investigation of how R406W affects tau's interactions with known binding partners (HSP90AB1, GSK3B). Future research should prioritize establishing clear pathogenicity criteria through functional assays and expanding clinical databases to enable precision medicine approaches for carriers of this variant. --- ## Agent Findings ### Literature (1) - **2026-07-14:** None of the provided papers are directly relevant to the TAU R406W variant. While several papers discuss tau pathology, MAPT regulation, and genetic variants in Alzheimer's disease, none specifically examine or mention the R406W mutation in the tau protein, which would be critical for understanding this particular variant's role in AD. ### Clinical (1) - **2026-07-14:** ### Structural (1) - **2026-07-15:** AlphaFold structure update: Baseline check: 9 structure(s) found ### Synthesis (1) - **2026-07-15:** Synthesis of 5 findings (clinical, literature, peptides, structural, supplements): The TAU R406W variant represents an Alzheimer's disease-associated mutation with significant therape... --- *Generated by [Clarity Protocol](https://clarityprotocol.io)* **Data Sources:** - Structure predictions: AlphaFold via ColabFold - Clinical variant data: ClinVar, gnomAD - Disease associations: Open Targets Platform - Research findings: AI agents (PubMed, clinical databases)